Congestive Heart FailureElevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction☆,☆☆
Section snippets
Study population and definitions
We studied 58 patients undergoing cardiac catheterization for a variety of clinical indications. There were no specific inclusion criteria other than a willingness to provide informed consent. The study protocol was approved by the institutional review board of the medical school. The clinical indications for catheterization included chronic stable angina (n = 24), atypical chest pain but an abnormal stress test (n = 20), CHF (n = 12), and evaluation of syncope (n = 2). An LVEF ≥0.55 was
Results
Of the 58 patients analyzed, 32 had no CHF and a normal LVEF (group 1), 14 had no CHF but depressed LVEF (group 2), and 12 had clinical CHF (group 3). Baseline characteristics for these groups are shown in Table I.Empty Cell Group 1 (n = 32) Group 2 (n = 14) Group 3 (n = 12) Age (y) 60 ± 2.4 61.6 ± 3.2 56.6 ± 5.7 Sex (male) 21 (66) 11 (79) 7 (58) Race (white) 26 (81) 9 (64) 9 (75) EF (%) 70.1 ± 1.6 43.1 ± 3.1* 30.8 ± 3.8* Coronary disease 17 (53) 10 (71) 5 (42) CAD score 1.2 ± 0.2
Discussion
Although elevated levels of IL-6 have been reported in patients with symptomatic CHF,3, 4, 5, 6, 7 a relationship between IL-6 and asymptomatic LV dysfunction has not been clearly defined. In our study cohort, we found elevated IL-6 levels in patients with LV systolic dysfunction but without any prior episodes of CHF. The magnitude of these elevations is intermediate between those with normal LV function and the levels reported for patients with CHF, both in this study and in previous reports.3
Acknowledgements
We thank William Boucher for performing the IL-6 measurements at the Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass. We also acknowledge the invaluable support of the technical and nursing staff in the cardiac catheterization laboratory.
References (14)
- et al.
Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD)
J Am Coll Cardiol
(1996) - et al.
Circulating interleukin-6 in severe heart failure
Am J Cardiol
(1997) - et al.
Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy
Am J Cardiol
(1998) - et al.
Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
Am J Cardiol
(1996) - et al.
Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure
J Am Coll Cardiol
(1998) - et al.
Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure
Am J Cardiol
(2000) - et al.
Elevated plasma interleukin-6 levels in patients with acute myocardial infarction
Am Heart J
(1993)
Cited by (83)
Proteomic Biomarkers of Heart Failure
2018, Heart Failure ClinicsCitation Excerpt :Cardiac IL-6 expression is reported to increase in advanced HF, suggesting a potential role in prognosis.98 In addition, increased IL-6 levels have been associated with left ventricular dysfunction before HF diagnosis, highlighting its potential utility as a risk marker for the onset and progression of HF.99 This prognostic ability has been confirmed in acute HF for prediction of short-term and long-term mortality, both as a sole biomarker and in a multimarker approach when combined with NTproBNP.100
Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment
2015, Pharmacology and TherapeuticsKinin-kallikrein system: New perspectives in heart failure
2024, Heart Failure ReviewsEffect of C-reactive protein on the risk of Heart failure: a mendelian randomization study
2023, BMC Cardiovascular Disorders
- ☆
Supported in part by a young investigator grant from Merck & Co., Inc (Whitehouse Station, NJ) to E. N. D.
- ☆☆
Reprint requests: Efthymios N. Deliargyris, MD, Cardiac Catheterization Laboratory, Administrative Offices, Room 2227, UNC Hospitals, 101 Manning Dr, Chapel Hill, NC 27514. E-mail: [email protected]